News | Magnetic Resonance Imaging (MRI) | July 12, 2016

ACR Manual on Contrast Media Addresses FDA Gadolinium Safety Concerns

Updated resource for radiologists guides safe, effective use of contrast media in daily practice

gadolinium, ACR Manual on Contrast Media, update, FDA safety concerns

July 12, 2016 — The updated American College of Radiology (ACR) Manual on Contrast Media contains a statement addressing the U.S. Food and Drug Administration (FDA) safety communication on use of gadolinium-based contrast agents for magnetic resonance imaging (MRI).

Gadolinium-based contrast agents are administered to approximately 30 million patients every year to improve the diagnostic accuracy of MR examinations. Researchers have found that gadolinium-based contrast agents may leave deposits in the brain, bone and other organs. “If the decision is made to use a gadolinium-based contrast agent for an MRI study for an individual patient, multiple factors need to be considered … including diagnostic efficacy, relaxivity, rate of adverse reactions, dosing/concentration and propensity to deposit in more sensitive organs, such as the brain,” notes a joint statement from the ACR and the American Society of Neuroradiology (ASNR).

“This vital guide for radiologists enhances the safe and effective use of contrast media in daily practice to ensure optimal patient care,” said Jacqueline Bello, M.D., FACR, chair of the ACR Commission on Quality and Safety. “The timely inclusion of the ACR and ASNR joint statement addresses questions posed by many radiology professionals about gadolinium-based contrast agents in the previous months,” she added.

“Reviews from radiologists show that this reference on contrast media is a practical and valuable resource in support of the millions of radiological examinations that may be assisted by intravascular contrast media annually,” said James H. Ellis, M.D., FACR, chair of the ACR Committee on Drugs and Contrast Media. He noted that the manual continues to be available for free as a frequently updated downloadable document on the ACR website.

Version 10.2 of the resource for using contrast media in diagnostic imaging includes:

  • An updated footnote in “Metformin,” concerning the FDA’s April 2016 guidance on patients who take this medication and who receive iodinated contrast media;
  • Information and new references about intra-osseous injection in “Injection of Contrast Media”; and
  • The addition of a document version history, so users may track changes from version to version.

For more information: www.acr.org

Related Content

Siemens Healthineers, Compressed Sensing technology, MRI, FDA approval, RSNA 2017
Technology | Magnetic Resonance Imaging (MRI)| February 21, 2017
Siemens Healthineers announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Compressed...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Siemens Healthineers, Magnetom Sempra MRI system, FDA approval, RSNA 2017
Technology | Magnetic Resonance Imaging (MRI)| February 17, 2017
Siemens Healthineers announced that the U.S. Food and Drug Administration (FDA) has cleared the Magnetom Sempra 60-cm 1...
Sir Peter Mansfield, early MRI trials, obituary, University of Nottingham

Sir Peter Mansfield during the original MRI trials. Image courtesy of the University of Nottingham.

Feature | Magnetic Resonance Imaging (MRI)| February 09, 2017 | Jeff Zagoudis
February 9, 2017 — Sir Peter Mansfield, FRS, whose research aided the development of...
GE Healthcare, Freelium technology, MRI magnet cooling, RSNA 2016, RSNA 2017
News | Magnetic Resonance Imaging (MRI)| February 06, 2017
At the 2016 Radiological Society of North America (RSNA) annual meeting, GE Healthcare unveiled Freelium, a magnet...
Technology | Advanced Visualization| February 06, 2017
February 6, 2017 — At the Society of Cardiac Magnetic Resonance (SCMR) 20th Annual Scientific Sessions, GE Healthcare
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Arterys, Cardiac MRI, cardiac MRI advances

An example of the Arterys blood flow imaging assessment software that can help automate cardiac MRI. 

Feature | Cardiac Imaging| January 16, 2017 | Dave Fornell
Each year imaging system manufacturers use the Radiological Society of North America (RSNA) meeting at the end of the
Arterys, Cardio DL cloud application, automated ventricle segmentation, MRI, FDA clearance
Technology | Advanced Visualization| January 09, 2017
Arterys has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Arterys Cardio DL...
Overlay Init